According to statistics, the number of diabetes patients in the world has reached 425 million in 2017.It is estimated that the number of diabetes patients in the world will reach 629 million in 2045.Diabetes medicine is one of the largest drug markets in the world.Among them, injection medicine (insulin, GLP-1) totaled 29 billion US dollars, accounting for 69%; oral preparations (DPP-4, SGLT-2) totaled US $13 billion, accounting for 31%.
Semaglutide is a human GLP-1 analogue currently in development for the treatment of T2D, with a similar structure to liraglutide. Semaglutide reduces HbA1c, systolic blood pressure, and body weight.After 12 weeks of treatment, semaglutide decreased fasting and postprandial glucose by increasing insulin production and decreasing glucagon secretion (which is normally associated with increases in blood sugar). Semaglutide also lowers fasting triglycerides and VLDL cholesterol, exerting beneficial effects on cardiovascular health.
In Novo Nordisk's half year 2020 financial report, semaglutide injection (Ozempic) has been listed in 43 countries around the world.In the first half of 2020, sales increased by 152% to US $1.5 billion. Sales of liraglutide (Victoza) fell 18% to $1.47 billion. In addition, sales of oral semaglutide (Rybelsus) just approved in 2019 will reach US $92 million.
According to the prediction of Evaluate Pharma, GLP-1 and SGLT-2 will occupy half of the world's top 10 hypoglycemic drugs in 2024. Global sales of semaglutide injection(Ozempic) are expected to reach $5.28 billion by 2024, and oral semaglutide (Rybelsus) is expected to reach $3.23 billion.
If there is any copyright infringement, please contact us and we will remove the content at the first time.
Sinopeg provide semaglutide and liraglutide. The product has high purity and complete quality system, which can meet the clinical application. If you need help, please contact us!
